← Back
$APLS All transactions

Apellis Pharmaceuticals, Inc.

J 10b5-1 Plan

$ Value

$0

Shares

3,837

Price

$0

Filed

Sep 19

Insider

Name

Dunlop A. Sinclair

Title

CIK

0001721108

Roles

Director

Transaction Details

Transaction Date

2025-09-19

Code

J

Table

Non-Derivative

Ownership

Indirect

Equity Swap

No

Shares After

65,071

Footnotes

These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Epidarex Capital I LP ("Epidarex") on June 20, 2025. | The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.73 to $23.27, inclusive. The reporting person hereby undertakes to provide, upon request, to the staff of the Securities and Exchange Commission, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. | The securities are held by Epidarex, and the reporting person, a general partner of Epidarex, may be deemed to have voting and dispositive power over the shares held by Epidarex. The reporting person disclaims beneficial ownership over the shares held by Epidarex except to the extent of his pecuniary interest therein. | Represents a stock distribution from Epidarex to a Limited Partner and General Partner of Epidarex, for no consideration.

Filing Info

Accession No.

0001193125-25-209537

Form Type

4

Issuer CIK

0001492422

Dunlop A. Sinclair's History

Date Ticker Type Value
2026-01-01 APLS A $0
2026-01-01 APLS A $0
2025-10-10 APLS $738K
2025-10-10 APLS J $0
2025-09-30 APLS $702K
2025-09-30 APLS J $0
2025-09-19 APLS $714K
2025-09-19 APLS J $0
2025-06-24 APLS J $0

Other Insiders at APLS (90d)

Insider Bought Sold Last
Dolsten Mikael 2026-02-27
Watson David O.
General Counsel
2026-01-28
Deschatelets Pascal
Chief Scientific Officer
2026-01-28
Francois Cedric
Chief Executive Officer
2026-03-11
Sullivan Timothy Eugene
Chief Financial Officer
2026-04-17
O'Brien Stephanie Monaghan 2026-04-06
Nicholson Nur
Chief Technical Officer
2026-01-28
Chopas James George
VP/Chief Accounting Officer
2026-01-28
DeLong Mark Jeffrey
Chief Business & Strat Officer
$8K 2026-02-11
Boucher Kelley
Chief People Officer
2026-01-28
MELTZER LESLIE
Chief Research and Development
2026-01-28